Jonathan Baden
Overview
Explore the profile of Jonathan Baden including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
511
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hadd A, Silvestro A, McKelvey B, Baden J, Bormann Chung C, Brown B, et al.
Clin Transl Sci
. 2025 Mar;
18(3):e70185.
PMID: 40070025
The use of a liquid biopsy to assess molecular residual disease (MRD) of solid tumors holds significant promise for improving outcomes for patients with cancer. Liquid biopsies are a minimally...
2.
Schenker M, Burotto M, Richardet M, Ciuleanu T, Goncalves A, Steeghs N, et al.
J Immunother Cancer
. 2024 Aug;
12(8).
PMID: 39107131
Background: Checkpoint inhibitor therapy has demonstrated overall survival benefit in multiple tumor types. Tumor mutational burden (TMB) is a predictive biomarker for response to immunotherapies. This study evaluated the efficacy...
3.
He J, Kalinava N, Doshi P, Pavlick D, Albacker L, Ebot E, et al.
J Immunother Cancer
. 2023 Nov;
11(11).
PMID: 38035725
Background: An accumulation of somatic mutations in tumors leads to increased neoantigen levels and antitumor immune response. Tumor mutational burden (TMB) reflects the rate of somatic mutations in the tumor...
4.
Hernandez K, Bramlett K, Agius P, Baden J, Cao R, Clement O, et al.
J Mol Diagn
. 2023 Feb;
25(3):143-155.
PMID: 36828596
The Blood Profiling Atlas in Cancer (BLOODPAC) Consortium is a collaborative effort involving stakeholders from the public, industry, academia, and regulatory agencies focused on developing shared best practices on liquid...
5.
Leiman L, Baden J, DAuria K, Lin C, Meier K
Expert Rev Mol Diagn
. 2022 Aug;
22(7):677-679.
PMID: 35979936
No abstract available.
6.
Merino Vega D, Nishimura K, Zariffa N, Thompson J, Hoering A, Cilento V, et al.
JCO Precis Oncol
. 2022 Aug;
6:e2100372.
PMID: 35952319
Purpose: As immune checkpoint inhibitors (ICI) become increasingly used in frontline settings, identifying early indicators of response is needed. Recent studies suggest a role for circulating tumor DNA (ctDNA) in...
7.
Owonikoko T, Park K, Govindan R, Ready N, Reck M, Peters S, et al.
J Clin Oncol
. 2021 Mar;
39(12):1349-1359.
PMID: 33683919
Purpose: In extensive-disease small-cell lung cancer (ED-SCLC), response rates to first-line platinum-based chemotherapy are robust, but responses lack durability. CheckMate 451, a double-blind phase III trial, evaluated nivolumab plus ipilimumab...
8.
Merino D, McShane L, Fabrizio D, Funari V, Chen S, White J, et al.
J Immunother Cancer
. 2020 Mar;
8(1).
PMID: 32217756
Background: Tumor mutational burden (TMB), defined as the number of somatic mutations per megabase of interrogated genomic sequence, demonstrates predictive biomarker potential for the identification of patients with cancer most...
9.
Baden J, Adams S, Astacio T, Jones J, Markiewicz J, Painter J, et al.
J Urol
. 2011 Sep;
186(5):2101-6.
PMID: 21944123
Purpose: The inadequacies of prostate specific antigen testing have created a need for novel markers for prostate cancer screening. The investigational ProCaM™ prostate cancer methylation assay detects aberrant methylation of...
10.
Baden J, Green G, Painter J, Curtin K, Markiewicz J, Jones J, et al.
J Urol
. 2009 Jul;
182(3):1186-93.
PMID: 19625061
Purpose: Prostate specific antigen tests have low specificity, which frequently results in unnecessary biopsy and typically limits screening to patients with prostate specific antigen greater than 4.0 ng/ml. We evaluated...